Impaired Interleukin-27-Mediated Control of CD4+ T Cell Function Impact on Ectopic Lymphoid Structure Formation in Patients With Sjögren's Syndrome

Arthritis Rheumatol. 2020 Sep;72(9):1559-1570. doi: 10.1002/art.41289. Epub 2020 Jul 21.

Abstract

Objective: Ectopic lymphoid structures (ELS) develop at sites of infection, autoimmunity, and cancer. In patients with Sjögren's syndrome (SS), ELS support autoreactive B cell activation and lymphomagenesis. Interleukin-27 (IL-27) is a key regulator of adaptive immunity and limits Th17 cell-driven pathology. We undertook this study to elucidate the role of IL-27 in ELS formation and function in autoimmunity using a murine model of sialadenitis and in patients with SS.

Methods: ELS formation was induced in wild-type and Il27ra-/- mice via salivary gland (SG) cannulation of a replication-deficient adenovirus in the presence or absence of IL-17A neutralization. In SG biopsy samples, IL-27-producing cells were identified by multicolor immunofluorescence microscopy. Lesional and circulating IL-27 levels were determined by gene expression and enzyme-linked immunosorbent assay. The in vitro effect of IL-27 on T cells was assessed using fluorescence-activated cell sorting and cytokine release.

Results: In experimental sialadenitis, Il27ra-/- mice had larger and more hyperactive ELS (focus score; P < 0.001), increased autoimmunity, and an expanded Th17 response (P < 0.001), compared to wild-type mice. IL-17 blockade in Il27ra-/- mice suppressed the aberrant ELS response (B and T cell reduction against control; P < 0.01). SS patients displayed increased circulating IL-27 levels (P < 0.01), and in SG biopsy samples, IL-27 was expressed by DC-LAMP+ dendritic cells in association with CD3+ T cells. Remarkably, in SS T cells (but not in T cells from patients with rheumatoid arthritis or healthy controls), IL-27-mediated suppression of IL-17 secretion was severely impaired and associated with an aberrant interferon-γ release upon IL-27 stimulation.

Conclusion: Our data indicate that the physiologic ability of IL-27 to limit the magnitude and function of ELS through control of Th17 cell expansion is severely impaired in SS patients, highlighting a defective immunoregulatory checkpoint in this condition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae Infections / immunology
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • CD4-Positive T-Lymphocytes / immunology*
  • Disease Models, Animal
  • Female
  • Gene Expression Profiling
  • Humans
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / immunology*
  • Interleukin-27 / genetics
  • Interleukin-27 / immunology*
  • Interleukin-27 / pharmacology
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / immunology
  • Male
  • Mice
  • Mice, Knockout
  • Middle Aged
  • RNA, Messenger / metabolism
  • Receptors, Interleukin / genetics
  • Salivary Glands / immunology*
  • Salivary Glands / metabolism
  • Salivary Glands / pathology
  • Sialadenitis / immunology
  • Sialadenitis / pathology
  • Sjogren's Syndrome / immunology*
  • Sjogren's Syndrome / pathology
  • Tertiary Lymphoid Structures / immunology*
  • Tertiary Lymphoid Structures / pathology
  • Th17 Cells / immunology*

Substances

  • Il17a protein, mouse
  • Il27ra protein, mouse
  • Interleukin-17
  • Interleukin-27
  • RNA, Messenger
  • Receptors, Interleukin